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ARTICLE OPEN
Incorporation of tetanus-epitope into virus-like particles
achieves vaccine responses even in older recipients in models of
psoriasis, Alzheimer’s and cat allergy
Andris Zeltins1, Jonathan West2, Franziska Zabel4,5, Aadil El Turabi 6, Ina Balke1, Stefanie Haas4, Melanie Maudrich4, Federico Storni8,
Paul Engeroff8, Gary T. Jennings4,5, Abhay Kotecha 7, David I Stuart7, John Foerster2,3 and Martin F. Bachmann3,4,5,6,8
Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective
alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in
elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-
tolerance in therapeutic vaccines. Their efﬁcacy could be increased even further by the incorporation of an epitope stimulating T
cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the
incorporation of foreign epitopes difﬁcult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic
plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMVTT) retain self-
assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMVTT-based vaccines can
deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines
against chronic inﬂammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer’s, β-amyloid), and
allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efﬁcient in vivo, observed even
in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMVTT-VLPs,
conﬁrming recognition of the incorporated Tetanus epitope. The CMVTT-VLP platform is adaptable to almost any antigen and its
features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations.
npj Vaccines  (2017) 2:30 ; doi:10.1038/s41541-017-0030-8
INTRODUCTION
Vaccines are widely used prophylactically to prevent infectious
disease, as well as therapeutically to alter the course of established
chronic infections. While passive immunization in the form of
monoclonal antibodies (“biologics”) has had a dramatic impact on
non-infectious diseases, including cancer, chronic inﬂammatory,
and neurodegenerative disease, the development of vaccines in
these increasingly important therapeutical areas has only very
recently been explored clinically. The term ‘therapeutical vaccine’
has been used to denote vaccines aiming at blocking an
endogenous molecular pathway in order to alter the course of
an already established non-infectious condition. This approach
represents a potentially attractive public health option as it could
offer an affordable alternative to several mAb therapies (chapter
54 in ref. 1). Examples include vaccines against angiotensin to
treat hypertension,2,3 TNFα to treat arthritis,4 IFNα to treat lupus,5
or IL-1β to treat diabetes.6 Such vaccines have been designed
using a variety of strategies, including DNA-vaccination, coupling
to non-speciﬁc adjuvants such as keyhole limpet hemocyanin
(KLH), or virus-like particles (VLP, reviewed in7). However,
inconsistent neutralizing capacity of vaccine-induced target-
speciﬁc antibodies has often been found limiting. This may be
due to a combination of factors, including the absence of
good Th cell epitopes within the vaccine conferring good Th cell
help to B cells,8–10 difﬁculties to bypass self-tolerance, as well as
poor vaccine responses in an aging demographic due to
immunosenescence.
Regarding bypassing of self-tolerance we have previously
shown that the use of VLPs as antigen-carrier confers robust B
cell activation, by mimicking the repetitive three-dimensional
scaffold common to viral intruders.7,11,12 Building on this work, we
here sought to explore whether incorporation of a strong T-cell
epitope might deliver enhanced T cell help to B cells even under
limiting conditions, such as aged vaccine recipients. The T-cell
epitope derived from the tetanus toxin (TT) is uniquely capable of
delivering such intrinsic immuno-boosting, since pre-existing T
cell memory to this epitope is near universal in humans and has
been used as such in vaccines.13,14 However, internal genetic
fusion of this epitope to a viral envelope protein has not been
reported and is not trivial since the capacity for self-assembly of
icosahedral particles from VLP monomer proteins is highly
sensitive to altered geometry. The search for suitable parent virus
Received: 10 May 2017 Revised: 4 September 2017 Accepted: 15 September 2017
1Latvian Biomedical Research & Study Centre, Ratsupites iela 1, Riga LV 1067, Latvia; 2Medical School University of Dundee, Dundee, UK; 3HealVax GmbH, Bahnhofstrasse 138808
Pfäfﬁkon, Switzerland; 4HypoPet AG, c/o Universität Zürich, Moussonstrasse 2, 8044 Zürich, Switzerland; 5Saiba GmbH, Alte Tösstalstr. 20, 8487 Rämismühle, Switzerland; 6The
Jenner Institute, University of Oxford, Oxford, UK; 7Division of Structural Biology, University of Oxford, Oxford, UK and 8Immunology, RIA, Inselspital, University of Bern, Bern,
Switzerland
Correspondence: John Foerster (J.Foerster@dundee.ac.uk) or Martin F. Bachmann (martin.bachmann@me.com)
Andris Zeltins and Jonathan West contributed equally to this work.
John Foerster and Martin F. Bachmann jointly supervised this work.
www.nature.com/npjvaccines
Published in partnership with the Sealy Center for Vaccine Development
shells is further complicated by additional constraints required to
obtain a platform adaptable to clinical applications including the
avoidance of human pathogenic virus species, as this may perturb
classical vaccination programs or interfere with diagnostics.
Furthermore, selection of a sufﬁciently large VLP-monomer
protein would increase the overall number of additional potential
Th cell epitopes derived from the VLP itself.
Here we demonstrate that VLPs derived from Cucumber Mosaic
Virus can be engineered to incorporate an internally fused Tet-
epitope. Vaccines based on the resultant VLPs (CMVTT) are stable,
immunogenic, and elicit strong responses even under limiting
conditions. In terms of safety of plant virus-derived VLP, a recent
clinical trial employing a plant-derived VLP-vaccine to treat
malaria did not identify limiting safety aspects.15 Cucumber
mosaic virus is a widely distributed virus with no toxicity to
humans reported to date. In addition, there are several studies
using CMV-derived vaccines in mammals including pigs, without
identifying toxicity.16 CMVTT can easily be linked to any antigen of
choice via chemical cross-linking. As such, this new technology
should signiﬁcantly increase the utility of vaccine approaches both
for the efﬁcient targeting of signaling pathways in vivo, as well as
for other clinical applications.
RESULTS AND DISCUSSION
Construction of a stable VLP containing a universal T cell epitope
We set out to engineer a VLP particle maintaining structural
stability as well as the capacity for self-assembly even after
incorporation of an artiﬁcial sequence into the envelope protein
monomers. In addition, in order to be adaptable to a wide range
of applications, the ideal VLP would (1) be derived from a non-
human parent virus, (2) retain the capacity to incorporate RNA
able to serve as immuno-stimulatory TLR agonist RNA,17,18 and (3)
exhibit a large molecular size monomer to increase the overall
number of T-cell stimulatory epitopes. Based on these criteria, we
screened several candidate plant virus derived VLPs harboring
large (25–30 kDa) monomer blocks, almost twice the molecular
weight of e.g., RNA-phage derived VLPs. Several candidate VLPs
exhibited dramatically reduced or absent VLP stability upon
insertion of the Tetanus-derived epitope (TT) at various sites
(Suppl. Fig. 1). In contrast, replacement of the ﬁrst 12 N-terminal
amino acids of CMV with the TT epitope resulted in well
assembled VLPs with a size of approximately 30–40 nm in
diameter, as shown by electron microscopy (EM) (Fig. 1a) and
dynamic light scattering (DLS) (Fig. 1b), preserving the native T = 3
icosahedral structure. SDS-PAGE analysis revealed a homogenous
product of the expected size (Fig. 1c). Ethidium bromide staining
Fig. 1 Properties of CMVTT virus-like particles. a Electron microscopy image of puriﬁed VLPs incorporating the universal T-cell epitope (Gln Tyr
Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu) derived from Tetanus toxin. VLP sample (1.5 mg/ml) was adsorbed on carbon formvar-coated
copper grids and were negatively stained with 1% uranyl acetate aqueous solution. The grids were examined using a JEM-100C electron
microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 80 kV. White bar corresponds to 100 nm. Particle size was found between 26 and
28 nm. b Dynamic light scattering (DLS) analysis of CMVTT. Sample VLP solution (1mg/ml) was analyzed on a Zetasizer Nano ZS instrument
(Malvern Instruments Ltd, UK). The results of three measurements were analyzed by DTS software (Malvern, version 6.32). The average
hydrodynamic diameter (Z(av)) of particles was found 38.5 nm. c SDS-PAGE analysis of CMVTT VLPs. Increasing amounts of VLPs were loaded
on the gel (lane 1–0.6 µg, lane 2–1.2 µg and lane 3–2.4 µg). M—protein size marker (Page Ruler Plus, Thermo Scientiﬁc). Samples were derived
from the same experiment and were processed in parallel. d Agarose gel analysis of CMVTT. Lane 1 – CMV VLPs (4 µl, 1.5 mg/ml) were mixed
with DNA Loading buffer (lane 1) and analyzed in 0.8% agarose /TBE buffer. M – DNA size marker (Gene Ruler, 1 kb, Thermo Scientiﬁc). Samples
were derived from the same experiment and were processed in parallel. e UV spectroscopy. The UV spectrum of VLP solution (1mg/ml) was
recorded using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, USA). The VLP sample absorbs strongly at
260 nm which is typical for viruses and VLPs. f For mass spectrometric (MS) analysis CMVTT VLPs (1 mg/ml) were diluted with a 3-
hydroxypicolinic acid matrix solution and were spotted onto an MTP AnchorChip 400/384TF. Matrix-assisted laser desorption/ionization
(MALDI)-TOF MS analysis was carried out on an Autoﬂex MS (Bruker Daltonik, Germany). The protein molecular mass (MM) calibration standard
II (22.3–66.5 kDa; Bruker Daltonik) was used for mass determination. Obtained spectrum suggests that the ﬁrst methionine is removed during
the CMV coat protein synthesis in E. coli cells and the N-terminus is replaced by the TT epitope (calculated MW 24485 Da, found m/z value
24487.3 Da)
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Fig. 2 Structure resolution of engineered CMV VLPs by cryoEM. VLPs were dissolved in borate-EDTA containing buffer, vitriﬁed and analyzed
by EM using a Tecnai F30 ‘Polara’ microscope (FEI) a Representative 2-D view of vitriﬁed VLP, generated from repeated imaging each ﬁeld of
view along the Z- axis creating a series of images (constituting a movie). From ~300 movies, 6685 particles were selected for data processing.
b Examples of generated 2-D classiﬁcation, 20 were generated based on average electron density. White bar corresponds to 50 nm. Cross
sectional Selection reﬁnement towards 3-D electron density model and an initial model ﬁtting data to icosahedral symmetry produced 9 Å
model. c High level reﬁnement further improved resolution to 4.2 Å. In addition, d the internal view reveals ordered elements (shown in
orange) are visible on the interior of the capsid shell. e Resolution Fitting reconstruction reveals that the obtained structure corresponds to X-
ray crystal structural data
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(Fig. 1d) and UV spectroscopy (Fig. 1e) conﬁrmed preserved RNA
incorporation. Mass spectroscopy conﬁrmed one major peak of
the expected size (Fig. 1f). CMVTT-VLPs were stable for at least
12 weeks both at −20 °C or 4 °C (Suppl. Fig. 2). This was further
conﬁrmed by DLS analysis showing stability with only a low
tendency to aggregate generation as indicated by a second peak
with increased mean hydrodynamic size (Z (av)).
Structure of CMVTT VLPs
We next characterized the molecular structure of the newly
generated CMVTT VLPs by cryoEM. High resolution images were
captured (Fig. 2a) and more than 6600 VLPs were picked for
averaging, resulting in several 2D classes of VLPs (Fig. 2b); the best
of these were used for 3D- classiﬁcation. This allowed construction
of a 9 Å model, followed by reﬁnement to 4.2 Å (Figs. 2c, d), and
ﬁtting of the primary sequence into the structure (Fig. 2e). The
structure of CMVTT appeared largely identical to the parent CMV
particles (RMSD 1.8 Å), particularly at the surface. Speciﬁcally, the
subunit arrangement of the asymmetric unit (chains A, B and C)
was identical between the parent virus and the modiﬁed VLPs. The
AA dimers were arranged at the 5-fold axis and the BC dimers
around the 3-fold/ pseudo 6-fold axis. Upon closer inspection
there were minor differences in the spatial location of the
backbone polypeptide in the capsid interior, most likely due to the
lack of native viral capsid–genome interactions in the recombi-
nant VLPs. Instead, the modiﬁed VLP exhibited additional electron
density displaying 3-fold symmetry within the interior cavity (Fig.
2d, orange color), indicative of novel ordered structures, most
likely reﬂecting tightly bound internal RNA. Interestingly, their
relative location and resemblance to tightly-associated RNA
species would suggest they might contribute towards stabilizing
of intra-subunit associations underlying the overall stability of the
particles. A further intriguing aspect of the structure is the
relatively large pore size, which may allow for the exchange of
naturally bound RNA by other poly-anions or other cargo.
A straightforward method to display antigens of choice on the
surface of VLPs is through chemical coupling to surface exposed
Lys. We therefore mapped all surface exposed Lys in the VLP-
structure (Fig. 3a). Next, FITC conjugation to CMVTT, followed by
trypsin-digest and MS was used to identify Lys residues
functionally available for coupling. This showed that 4 of 8 tryptic
peptides generated were detected with the FITC modiﬁcation (Fig.
3b). One surface located Lys-containing peptide (GSYYGKR, green
letters in Fig. 3b, Panel I) was completely modiﬁed by FITC. In all
other cases, both unmodiﬁed and FITC-modiﬁed peptide forms
were found. These results correspond well to the cryoEM structural
model, which shows several surface located Lys to be orientated
inwards thereby providing insufﬁcient space for multiple
crosslinker-VLP interactions. Ionic charge also was an efﬁcient
predictor of coupling, since two prominent surface exposed Lys
(equivalent to K79 and K116 in the wild type virus) located in
acidic patches did not couple to FITC, while K88 residing nearby
but with different charge was efﬁciently modiﬁed. Taken together,
these data provide an in-depth structural characterization of the
novel VLP-species and conﬁrm that ample surface-exposed lysine
residues are present to allow chemical cross-linking to antigenic
epitopes of choice.
Recognition of the universal T cell epitope in CMVTT by human
CD4+ T cells
In order to test recognition of the tetanus-derived universal T cell
epitope, human PBMCs were labeled with CFSE and stimulated
Fig. 3 Chemical reactivity of surface exposed Lysine residues and T cell reactivity of incorporated universal T cell epitope. a Surface
representation of cryoEM model with all lysine residues displayed in stick format, net surface charge is color coded. b Trypsin ﬁngerprint
analysis of CMV-Ntt830 VLPs after treatment with ﬂuorescein isothiocyanate (FITC). Panel I—CMV-Ntt830 protein sequence represented in the
form of trypsin peptides. Red—peptides identiﬁed after trypsin digest and mass spectrometric analysis; black—peptides not found; green—
peptide identiﬁed only in the form of FITC conjugate. The Ntt830 residues are underlined; Panel II—CMV-Ntt830 coat protein peptides found
as FITC conjugates (green Lys symbols) or partially cut by trypsin. c,d The universal T cell epitope in CMVTT is recognized by primary human
CD4+ T cells. c Human PBMCs from four individual donors were labeled with CFSE and cultured for 7 days upon stimulation with either CMV or
CMVTT and CFSE ﬂuorescence was assessed by ﬂow cytometry. Shown are representative scatterplots of CD4
+ T cells stimulated with either
CMV or CMVTT. d Normalized percentages of CFSE-CD4
+ T cells in 4 individual donors upon CMV (black) or CMVTT (gray) are displayed as
mean± SEM. *p< 0.01 in a two-tailed, unpaired student’s t test
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with either wild type or CMVTT followed by measurement of
proliferation by assessment of the frequency of CFSElow CD4+
T cells 7 days later. With each cell division, cellular CFSE-labeling is
reduced by 50% and CFSElow CD4+ T cells therefore represent
T cells having undergone cell division. The frequency of these cells
was much higher in PBMC cultures stimulated with CMVTT
compared to those stimulated with CMV wild type, in fact
comparable to proliferation of cells stimulated with pure tetanus
toxoid as positive control, thereby conﬁrming robust recognition
of the universal T cell epitope in CMVTT (Fig. 3c, left upper
quadrant and Fig. 3d). Therefore, incorporation of the universal T-
epitope in CMVTT boosts T-cell responses in randomly selected
primary human T cells.
Generation of a vaccine against psoriasis
We next proceeded to design clinically relevant vaccine proto-
types based on CMVTT to explore functional performance. First, we
focussed on Interleukin 17 A (IL17A), a pro-inﬂammatory cytokine.
Antibodies targeting IL17A are highly effective in psoriasis,
a skin condition affecting between 1 and 4 % in most global
populations.19 Despite an excellent safety and efﬁcacy proﬁle, the
high cost of IL17-targeting biologics severely restricts access to
this treatment. Replacing these antibodies by vaccination against
IL-17A therefore has the potential to vastly increase access to
treatment for a wide range of patients (reviewed in ref. 20) as well
as be useful for other conditions, as we have previously shown
using an earlier VLP-based IL17 vaccine.21 To test the performance
of a CMVTT based anti-IL17A vaccine for psoriasis, we ﬁrst
generated a vaccine prototype by conjugation of full-length,
dimeric murine IL-17A to CMVTT (Figure S3). Next, mice were
immunized with different doses of the IL-17 CMVTT vaccine
preparation, resulting in high anti-IL-17A IgG levels, after as low a
dose as 0.5 µg (Fig. 4a), but not to the most highly conserved IL17
isoform, IL-17F (Fig. 4b), conﬁrming high selectivity of the induced
response.
Preclinical efﬁcacy of the IL17CMVTT
We next assessed the ability of the vaccine to reduce psoriatic
disease in vivo, employing the widely used IL17-dependent
imiquimod model22 in a direct head-to-head comparison to a
high-afﬁnity monoclonal IL17 antibody. As shown in Fig. 4c, serial
measurement of ear thickness revealed an approximately 50%
reduction of ear swelling in animals receiving either protective
vaccination or treatment with IL17A antibody. The same was
observed in ex-vivo quantiﬁcation of epidermal thickness by
histology (Fig. 4d/e). Efﬁcacy of the vaccine was also equivalent to
the anti-IL17 antibody when tested in dorsal skin (Figure S4).
These data suggest that a CMVTT based IL17A-vaccine is
equipotent to a monoclonal anti-IL17A antibody in mice.
Immunogenicity under limiting conditions
In clinical practice, eliciting an effective immune response in the
vast majority of vaccine recipients can be a major challenge. In
psoriasis, an ageing demographic may contribute to a sub-optimal
immune responses. In order to obtain evidence whether
incorporation of the TT-epitope would boost immunogenicity in
poor responders, we emulated sub-optimal vaccine conditions,
both by reducing the vaccine dose to the threshold required for a
response (0.5 µg) and studying aged mice (10 months). Indeed, as
shown in Fig. 4f, we observed an increased formation of IL17A IgG
in response to vaccination in mice that had received a DPT-
vaccination prior to IL17A vaccination. The same trend was
independently observed in young mice (Figure S5). These data
suggest that inclusion of a tetanus-derived epitope augments
immunogenicity under limiting conditions.
Absence of endogenous IL-17 boosting, reversibility, and ability to
re-vaccinate
Finally, we characterized additional parameters important for
clinical applications. First, high local IL17A levels in the skin during
a psoriasis-ﬂare could theoretically cause an endogenous boosting
of anti-IL17A titerss. We therefore simulated a psoriasis ﬂare by
application of imiquimod cream to mice having received prior
anti-IL17A vaccination. However, we did not observe any effect of
this treatment on antibody titerss (Fig. 4g). Next, we determined
long-term titers kinetics. In conﬁrmation of previous experience
with VLP-type therapeutical vaccines in humans, anti-IL17A IgG
titerss were reversible after approximately 10 weeks (Fig. 4h).
Importantly, a single 3-monthly vaccine booster shot was able to
maintain IL17A IgG titerss (white symbols). Furthermore, an
alternative boosting regimen applied as single triple-boost after
six months was able to re-induce antibody titerss without causing
high titers ‘super boosting’. We conclude that CMVTT-based IL17A
vaccination results in potent, reversible, and re-boostable anti
IL17A IgG titers in mice, devoid of endogenous boosting during
psoriasis-like ﬂares.
Safety of IL17-vaccination
In terms of safety of an IL17-targeting vaccine approach, it is worth
noting that, to date, in excess of 5000 patients have been
continuously exposed to neutralizing anti-IL17 action (ixekizumab,
secukinumab, brodalumab) for at least ﬁve years as part of long-
term extension clinical trials as well as post-marketing. This
extensive clinical dataset has not identiﬁed any delayed-onset
safety aspects. This duration of IL17 neutralization by far exceeds
the expected duration of anti-IL17 suppression effected by a VLP-
vaccine based approach, suggesting the latter is unlikely to add
safety concerns. In terms of non-target related autoimmune-
issues, previous experience with VLP-based vaccines (angiotensin,
IL1-targeting vaccines) has not uncovered off-target non-speciﬁc
T-cell activation facilitating undesired autoimmune effects.
Although clinical trials will be required to conﬁrm safety, presently
available data therefore do not indicate principle safety limitations
of this approach.
Generation of a vaccine against cat allergy
Allergy to cats is highly prevalent and affects up to 10% of the
common population. It is not restricted to cat owners,23 and often
has major secondary effects on other atopic conditions such as
eczema or asthma. The currently available treatment, speciﬁc
immunotherapy, lacks consistent efﬁcacy and is fraught with
safety issues. Thus, widely available effective treatment for this
condition would have signiﬁcant health beneﬁts. The major
allergen responsible for most allergies against cats world-wide is
feline domesticus 1 (Fel d 1),24 a 35–39 kDa heterodimer.25 We
have previously shown that recombinant Fel d 1 displayed on
VLPs derived from the bacteriophage Qβ efﬁciently confers
protection in a murine model of cat allergy.26 To extend these
ﬁndings to CMVTT-VLPs, recombinant Fel d 1, produced as
described previously,26 was coupled to CMVTT via a small Cys
containing linker26 (Fig. 5a). To test the immunogenicity of the
vaccine, mice were immunized with Fel d 1 either soluble, mixed
with CMVTT particles or coupled to CMVTT particles. Fel d 1
coupled to CMVTT was highly immunogenic and induced a 10–100
fold stronger antibody response than free Fel d 1 or Fel d 1 mixed
with VLPs (Fig. 5b), demonstrating potent immunogenicity
depended on presentation by the CMVTT-VLP.
The main safety limitation of speciﬁc immunotherapy against
cat allergy is the risk of severe anaphylactic reactions. We
therefore tested whether Fel d 1 coupled to CMVTT would carry
a lower risk of anaphylaxis than free Fel d 1. To this end, we
stimulated basophils in whole blood from an allergic human
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donor with either free Fel d 1 or Fel d 1 conjugated to CMVTT and
assessed basophil activation. As expected, free Fel d 1 induced
strong basophil degranulation over a wide range of concentra-
tions (Fig. 5c). By contrast, degranulation after stimulation with
similar amounts of conjugate Fel-CMVTT was greatly reduced (Fig.
5d). Thus, VLP-coupling effectively reduces the anaphylactic
reactivity of this potent antigen.
The therapeutic potential of the vaccine Fel-CMVTT was tested
next. BALB/c mice were rendered allergic by injection of low doses
of natural Fel d 1 in Alum to induce Fel d 1 speciﬁc IgE. Mice were
then injected either with Fel d 1-CMVTT or unconjugated CMVTT as
a control. Two weeks after injection, mice were re-challenged with
the allergen and anaphylactic responsiveness was quantiﬁed intra-
vital by serial measurement of change in body core temperature
Tetanus-integrated VLP platform for therapeutic vaccination
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(Fig. 5e). Control mice that had received the VLP alone showed a
severe drop in temperature, indicative of a strong systemic allergic
reaction. In contrast, mice immunized with the vaccine Fel-CMVTT
were largely protected (Fig. 5e). Since desensitization to IgE
mediated cat allergy ranks as a challenging test for anti-
anaphylactic treatments, the data presented here suggest that
CMVTT exhibits favorable performance characteristics applicable to
the development of therapeutic vaccines for allergies.
Generation of a vaccine against Alzheimer’s disease
Alzheimer’s disease is one of the biggest issues in global health
care. In terms of pathogenesis, treatments targeting both tau-
protein (TauRx phase III), as well as β-amyloid27 have yielded
disappointing results in clinical trials. Based on recent study
results, it is possible that alternative and/or a combination of
pathways need to be targeted. In addition, early intervention,
preceding clinical symptoms, may be required. In terms of the
so-called amyloid hypothesis, there is evidence that early dosing
with antibodies speciﬁcally targeting N-terminal Aβ1–42 may be
effective.28 Clearly, frequent administration of antibodies over
decades in patients without clinical symptoms would be
impractical. By contrast, a prophylactic vaccination approach
could be a viable public health intervention. As most Alzheimer’s
patients are elderly, the CMVTT platform may confer signiﬁcant
advantages in terms of efﬁcacy. In order to obtain initial data
supporting this notion, we tested whether a CMVTT based vaccine
against Aβ1–6 would induce the species of antibodies thought to
be protective, that is, IgG antibodies recognizing aggregated
human Aβ1–42 in the brain of Alzheimer’s patients. To this end, we
coupled Aβ1–6, i.e., the N-terminus of Aβ1–42 to CMVTT (Aβ1–6-
CMVTT) or VLPs without the tetanus epitope (Aβ1–6-CMVWT, Fig.
6a). The control vaccine as such is analogous to the CAD106
vaccine currently undergoing clinical testing (NCT02565511), as
both are VLP-based vaccines coupled to the same epitope.
In order to show enhanced immunogenicity by vaccination with
Abeta-CMV containing the TT epitope, 8 weeks old C57BL/6 mice
were primed with Infanrix, a hexa-valent vaccine for children
against Tetanus and other infections e.g., diphtheria, pertussis,
hepatitis B, polio, and haemophilus inﬂuenza B. After four weeks,
mice either primed with Infanrix or left untreated were immunized
with 10 µg, 1 µg or 0.1 µg of Abeta-CMV TT vaccine and the anti-
Abeta IgG response in serum was analyzed (Fig. 6b). In comparison
to the unprimed control group, mice that were primed with
Infanrix showed an increased immune response especially early
on day 5 and 7 after vaccination against Abeta peptide
independent of the dose amount.
In order to study whether the increased immunogenicity also
holds true in older animals, six months old BALB/c mice were
either pre-immunized against Tetanus or left untreated as control
before immunization with 1 µg of Aβ1–6-CMVTT or Aβ1–6-CMVWT.
Vaccination with CMVTT compared to CMVWT vaccine already
induced a stronger response regardless of whether mice had been
primed against tetanus (Fig. 6c, compare “only Aβ -CMVTT” with
“Infanrix + Aβ-CMVWT”). Immunogenicity of Aβ-CMVTT vaccine was
even further increased when mice were primed against tetanus
(Fig. 6c, compare “Infanrix + Aβ-CMVTT” with “only Aβ-CMVTT”).
Thus, young and old mice immune to tetanus mount an enhanced
response to an Alzheimer’s vaccine based on CMVTT.
To assess whether the induced antibodies exhibited the right
speciﬁcity, serum antibodies of mice immunized with Aβ1–6-CMVTT
vaccine were tested for their ability to recognize plaques of Aβ in
brain sections from Alzheimer’s patients (Fig. 6d-f). Antibodies
induced by active immunization with the Aβ 1–6-CMVTT vaccine
(Fig. 6f) recognized Alzheimer’s plaques on human brain sections
similar to as a monoclonal antibody raised against Aβ peptide
1–17 (Fig. 6d). Serum from immunized but not control mice
recognized both Aβ1–42 by ELISA (not shown) as well as plaques in
brain sections from Alzheimer’s patients, indicating that Aβ1–6-
CMVTT was able to induce antibody responses of the desired
speciﬁcity (Fig. 6e,f).
METHODS
Ethics statement
All studies involving either animal and/or human samples were subject to
prior approval by the respective local ethics committees. For studies using
mice, methods were performed in accordance with relevant regulations
and guidelines. Methods were approved by the animal ethics research
committee of the University of Dundee as part of the standard operating
procedure for study approval for project licence 60/4944. Studies involving
human tissue for Alzheimer histology were overseen by KEK Zürich ethics
committee. Tissue was ascertained as part of a KEK-approved project
(Adriano-Aguzzi/i2016). According to local governance regulation, use of
anonymised slides for KEK-approved projecxts involving post mortem
tissue is not subject to post-hoc individual consenting.
Isolation and cloning of a coat protein (CP) of cucumber mosaic
virus (CMV)
The total RNA from CMV-infected lily leaves collected from a private
garden in Riga, Latvia, was isolated using TRI reagent (Sigma, Saint Louis,
USA) in accordance with manufacturer’s recommendations. For cDNA
synthesis, OneStep RT-PCR kit (Qiagen, Venlo, Netherlands) was used. For
ampliﬁcation of the CMV CP gene, the primer sequences were chosen
following analysis of CMV sequences from GenBank: CMcpF (CACCATG-
GACAAATCTGAA TCAACCAGTGCTGGT) and CMcpR (CAAAGCTTAT-
CAAACTGGGAGCA CCCCAGATGTGGGA); NcoI and HindIII sites
underlined. The corresponding PCR products were cloned into the
pTZ57R/T vector (Fermentas, Vilnius, Lithuania). E. coli XL1-Blue cells were
used as a host for cloning and plasmid ampliﬁcation. To avoid RT-PCR
errors, several CP gene-containing pTZ57 plasmid clones were sequenced
using a BigDye cycle sequencing kit and an ABI Prism 3100 Genetic
analyzer (Applied Biosystems, Carlsbad, USA). After sequencing, the cDNA
Fig. 4 Immunogenicity and speciﬁcity of the immune response generated by vaccination with a CMV-based anti IL17A vaccine in mice. a
Female C57B/6j mice aged 8 weeks (n= 4 per group) were immunized as detailed in the text and anti-IL17A IgG titers determined based on
half-maximal OD450 values, as previously described.18 b Speciﬁc IgG antibody titers ELISA assays of n= 4 mice were performed with plating
either recombinant murine IL17A (black circles) or IL17F (open circles). c The therapeutical effect of IL17A-vaccination on psoriasis-like disease
in mice. Female C57B/6j mice (n= 5 per group) were vaccinated three times (day 0, 14, 28) with 50 µl (2.5 µg) of vaccine. Two weeks after the
last vaccine booster, imiquimod cream was applied daily to the ears and dorsal skin (see Methods). Comparator groups were mice not
receiving any treatment, non-immunized mice receiving direct anti-IL17 antibody injection, and untreated mice, as indicated in the ﬁgure. Ear
thickness was determined on the days indicated. Data shown represent average ± s.d. *p< 0.05 (two-tailed T-test). d, representative H&E-
based histology of mice shown in c sacriﬁced on day 8. e. Quantiﬁcation of epidermal thickness in all samples. **p< 0.01. f The effect of
tetanus-pre-vaccination on IL17A-vaccine immunogenicity. Female C57/B6j mice at young (a, 10 weeks) or advanced (b, 10 months) age
received either no (open symbols) or DPT-prevaccination (closed symbols). Four weeks later, 0.5 µg of IL17A vaccine was administered on days
0,14,28 and IL17A titers determined by ELISA. *p< 0.05 (two-tailed t-test). g Endogenous boosting. Female C57B/6j mice (n= 5 per group)
received triple IL17A vaccination (0,2,4 weeks) followed by no treatment (dark shaded) or one week of imiquimod treatment (light shaded)
identical to that employed in Fig. 3. IL17A-IgG titers were measured by ELISA. h Long-term anti-IL17A titer kinetics. Female mice were
vaccinated at baseline (0,2,4 hatched arrows on bottom), followed by booster vaccination either as single injection every three months (white
symbols and arrows), or one single triple injection booster after six months (black symbols). Data shown are average and SEM
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of CMV CP gene without sequence errors coding for CMV coat protein was
then subcloned into the NcoI/HindIII sites of the pET28a(+) expression
vector (Novagen, San Diego, USA), resulting in the expression plasmid pET-
CMVWT.
To replace the original amino acids at the N-terminus of CMV CP against
foreign epitope sequences, as a template for PCR ampliﬁcation and
mutagenesis the pET-CMVWT plasmid was used. Internally in CMVWT gene
located SalI site (Fig.1) was used for cloning corresponding PCR products.
To introduce the tetanus toxoid epitope coding sequence in CMVWT
gene, two step PCR mutagenesis was necessary. For the ﬁrst step
ampliﬁcation following primers were used for PCR: pET-220 (agcaccgc
cgccgcaaggaa –upstream from pET28a+ polylinker, the ampliﬁed region
includes BglII site) and CMV-tt83-1R (ATTTGGAGTTGGCCTTAATATACT
GGCCCATGGTATATCTCCTTCTTAAAGT). For the second round the PCR
product from the ﬁrst round was diluted 1:50 and re-ampliﬁed with
primers pET-220 (SEQ ID NO: 11) and CMV-tt83Sal-R2 (GACGTC-
GACGCTCGGTAATCCCGATAAATTTGGAGTTG GCCTTAATATACTG).
To obtain CMV VLPs, E. coli C2566 cells (New England Biolabs, Ipswich,
USA) were transformed with the CMVTT CP gene-containing plasmid pET-
CMVTT. After selection of clones with the highest expression levels of target
protein, E. coli cultures were grown in 2xTY medium containing kanamycin
(25mg/l) on a rotary shaker (200 rev/min; Infors, Bottmingen, Switzerland)
at 30 oC to an OD600 of 0.8–1.0. Then, the expression was induced with 0.2
mM Isopropyl-β-D-thiogalactopyranoside (IPTG), and the medium was
supplemented with 5mM MgCl2. Incubation was continued on the rotary
shaker at 20 oC for 18 h. The resulting biomass was collected by low-speed
centrifugation and was frozen at -20 oC. After thawing on ice, the cells were
suspended in the buffer containing 50mM sodium citrate, 5 mM sodium
borate, 5 mM EDTA, 5 mM mercapto-ethanol (pH 9.0, buffer A) and were
disrupted by ultrasonic treatment. Insoluble proteins and cell debris were
removed by centrifugation (13,000 rpm, 30min at 5 oC). The soluble CMVTT
CP protein in clariﬁed lysate was pelleted using saturated ammonium
sulfate (1:1, vol/vol) overnight at +4 oC. Soluble CMVTT CP-containing
protein solution was separated from the cellular proteins by ultracen-
trifugation (SW28 rotor, Beckman, Palo Alto, USA; at 25,000 rpm, 6 h, 5 oC)
in a sucrose gradient (20–60% sucrose in buffer A, without mercapto-
ethanol, supplemented with 0.5% Triton X-100). After dialysis of CMV-
containing gradient fractions, VLPs were concentrated using ultracen-
trifuge (TLA100.3 rotor, Beckman, Palo Alto, US; at 72,000 rpm 1 h, +5 oC) or
by ultraﬁltration using Amicon Ultra 15 (100 kDa; Merck Millipore, Cork,
Ireland). All steps involved in the expression and puriﬁcation of VLP were
monitored by SDS-PAGE using 12.5% gels.
Characterization of CMVTT VLPs
The concentration of puriﬁed CMVTT was estimated using the QuBit
ﬂuorometer in accordance with manufacturer’s recommendations (Invitro-
gen, Eugene, USA). Concentrated VLP solutions (approximately 3 mg/ml)
were stored at+ 4 oC in 5mM sodium borate, 2 mM EDTA, buffer (pH 9.0).
To demonstrate the presence of tetanus epitope in CMV VLPs, the mass
spectrometric analysis of the puriﬁed CMVTT (also referred to as CMV-
Ntt830) VLPs was used. The stability of VLPs was investigated by thermal
denaturation in the presence of SYPRO-orange dye using a DNA melting
point determination program and a real-time PCR system MJ Mini (Bio-Rad,
Hercules, USA). This involved subjecting VLP samples to increasing heat
whilst monitoring ﬂuorescence. The morphology of VLPs was conﬁrmed by
applying samples (0.1–0.5 mg/mL) on glow discharged carbon coated
copper grids and observing by transmission electron microscopy using
JEM-1230 electron microscope (JEOL, Tokyo, Japan). Average sizes of VLP
preparations were determined by dynamic light scattering, assessed by
diluting to 1 mg/ml and analyzing in Zetasizer Nano ZS instrument
(Malvern Instruments Ltd, Malvern, UK).
Trypsin-ﬁngerprint/mass spectrometry
Reactive Lys residues available for chemical coupling of antigens were
determined by FITC-labeling free amino groups, FITC-modiﬁed coat protein
was separated in SDS/PAGE gel, the fragment was excised from gel and
digested with trypsin (Trypsin Proﬁle IGD Kit, Sigma). VLPs (1.5 mg/ml in 50
mM Sodium borate, 2 mM EDTA, pH 9.0) were reacted with 20mM FITC at
Fig. 5 Generation of a vaccine against cat allergy. a Analysis of the recombinant Fel-CMVTT vaccine. SDS Page (NuPage 4–12% Bis-Tris) was run
under denaturing and reducing conditions. Lanes from left to right: 1-MW markers (Invitrogen, SeeBlue Prestained), 2-puriﬁed CMV VLP (~ 25
kDa coat protein monomer), 3-derivatized CMVTT-VLP after reaction with SMPH (bands in order of ascending size corresponding to VLP
monomers, dimers, trimers etc. resulting from cross-linking), 4-puriﬁed Fel d 1 (~20 kDa), 6/7-vaccine Fel-CMVTT following conjugation with Fel
d 1 protein, loaded amount of VLP 5 µg and 10 µg, 9/10-Fel-CMVTT after removal of uncoupled Fel d 1 by ultraﬁltration, loaded total protein
amount of VLP 5 µg and 10 µg. Samples were derived from the same experiment and were processed in parallel. b Immunogenicity
assessment in Balb/C mice that received 1 µg of Fel d 1 protein in three versions: free, mixed with or coupled to CMVTT intravenously on day 0.
Blood was collected on days 0, 7 and 14 and analyzed for Fel d 1 speciﬁc total IgG titers (OD50). c, d Basophil activation test was performed
with whole blood from a cat-allergic patient. Blood samples were incubated with different amounts of free recombinant Fel d 1 c or
recombinant Fel d 1 coupled to CMVTT d. Untreated, anti-FceRI, fMLP and natural Fel d 1 served as controls. e Fel d 1 allergen challenge in-vivo.
Mice were sensitized with natural Fel d 1 and vaccinated with Fel-CMVTT vaccine or CMVTT VLP alone. To show protection of sensitized mice
upon immunization, mice were challenged with 3 μg natural Fel d 1 in 150 μl PBS i.v. Mean temperature changes (°C) in Fel-CMVTT vaccine or
CMVTT-VLPs-vaccinated mice +/- SEM are shown (n= 5). After 40min CMVTT-vaccinated mice were sacriﬁced because of severe anaphylactic
symptoms
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+4 oC for 24 h. Samples after FITC treatment were separated in 12% SDS-
PAGE, protein spots after Coomassie staining excized from gel and treated
with Trypsin using Trypsin Proﬁle IGD Kit and protocol (Sigma, St Louis,
USA) ON +4 oC. The reaction mixture was puriﬁed using ZipTip tips (Merck
Millipore, Cork, Ireland), diluted with a 3-hydroxypicolinic acid matrix
solution and spotted onto an MTP AnchorChip 400/384TF. MALDI-TOF MS
analysis was carried out on an Autoﬂex MS (Bruker Daltonik, Bremen,
Germany). The protein molecular mass (MM) calibration standard I (3–20
Fig. 6 Immunogenicity of CMVTT – based Alzheimer’s vaccine. a SDS-PAGE analysis (NuPage 4–12% Bis-Tris) of the Aβ1–6-CMVTT (left panel) and
Aβ1–6 -CMV WT (right panel) vaccine was run under denaturing and reducing conditions. Lanes from left to right: 1/6 - MW markers
(Invitrogen, SeeBlue Prestained), 2-puriﬁed CMV VLP (~25 kDa coat protein monomer), 3-derivatized CMV-VLP after reaction with SMPH (bands
in order of ascending size corresponding to VLP monomers, dimers, trimers etc. resulting from cross-linking), 4/5-Aβ-CMV following
conjugation of the antigen amount loaded 5 µg (4) or 10 µg (5). Samples were derived from the same coupling experiment and were
processed in parallel. b Immunogenicity assessment in young mice. One group of eight weeks old female C57BL/6 mice were primed with
Infanrix and the other group was left untreated. After four weeks, mice were immunized with 10 µg, 1 µg or 0.1 µg of Aβ1–6 -CMVTT vaccine.
Blood was collected on day 0, 5, 7 and 14 and analyzed for Aβ-speciﬁc total IgG titers (endpoint). Mean values with SEM are shown of a
representative experiment with n= 2–5 as indicated. Signiﬁcances were obtained by a Mann Whitney test. c Immunogenicity assessment in
old mice. Six months old Balb/C mice were primed with Infanrix® or left untreated. After 3 weeks, mice received 1 µg of Aβ1–6-CMVTT or 1 µg of
Aβ1–6–CMV WT vaccine intravenously. Blood was collected on day 0, 3, 7 and 14 and analyzed for Aβ-speciﬁc total IgG titers (OD50). Mean
values with SEM are shown of a representative experiment with n= 8. Signiﬁcances with p< 0.05 were obtained by a Mann Whitney test. d–f
Immunohistochemistry of human brain section of the hippocampus showing the dentate gyrus with Cornu Ammonis of an Alzheimer’s
patient. Formalin-ﬁxed in parafﬁn embedded brain tissue of an Alzheimer’s patient was stained with d a mouse mAb generated against the Aβ
peptide 1–17 as a positive control, e naïve mouse serum from day 0 as negative control and f puriﬁed serum from mice immunized with Aβ-
peptide 1–6 (from N-terminus) coupled to CMVTT VLP from day 56. All samples were counterstained with hematoxylin. Dimensions are
depicted in pictures (100 µm). Arrows indicate single Aβ plaques
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kDa; Bruker Daltonik) and Peptide calibration standard II was used for mass
determination.
T cell proliferation assays
Blood was obtained from human volunteers and peripheral blood
mononuclear cells (PBMC) were isolated by density gradient centrifugation
on Ficoll Paque (GE Healthcare, Chalfont St. Giles, UK). PBMCs were labeled
with 10 µM CFSE (Biolegend, San Diego, CA, USA) according to the
manufacturer’s protocol and cultured in RPMI-1640 (Gibco, Basel, Switzer-
land) supplemented with 5% of heat-inactivated human AB serum (Swiss
Red Cross, Bern, Switzerland), 2 mM L-Glutamine (Biochrom, Berlin,
Germany), 50 U/ml penicillin and 50 µg/ml streptomycin (Bioconcept,
Allschwil, Switzerland). During 7 days, the cells were stimulated with either
1 µg/ml CMV WT or CMVTT or left untreated. T cells were then stained with
anti-CD3-PerCp-Cy5.5, anti-CD4-PE-Cy7 (Biolegend, San Diego, CA, USA),
data acquired with BD FACSCanto™ and analyzed with FACS-Diva
software (BD Biosciences, Franklin Lakes, NJ, USA). This study was
approved by the local ethics committee.
CryoEM reconstruction to determine CMVTT VLP structure
CMVTT (2.5 mg/ mL) in 5mM sodium borate, 2 mM EDTA, pH 9 was applied
for 20 s to glow-discharged holey carbon-coated copper grids (C-ﬂat, CF-2/
1–2 C; Protochips) in a humidiﬁed chamber (70% relative humidity), excess
sample being removed by blotting on to ﬁlter paper and grids rapidly
vitriﬁed by plunging in to liquid ethane (Vitrobot, FEI). Cryo-grids were
stored in liquid nitrogen prior to imaging with a Tecnai F30 Polara
microscope (FEI).
CryoEM images were collected using a Tecnai F30 ‘Polara’ microscope
(FEI) at 300 kV, equipped with an energy ﬁlter (GIF Quantum, Gatan)
operating in zero-loss mode (0–20 eV energy selecting slit) and a direct
electron detector (K2 Summit, Gatan). Movies (25 frames, each 0.2 s) were
recorded at 1.0–3.0 μm underfocus in single-electron counting mode with
SerialEM at a calibrated magniﬁcation of 37,037×, thus resulting in a pixel
size of 1.35 Å. Frames from each movie were aligned and averaged to
produce drift-corrected micrographs.27 Data are summarized in Table S1.
Structures were solved with RELION 1.3 according to recommended
gold-standard reﬁnement procedures,28 and icosahedral symmetry was
applied. Micrographs showing signs of astigmatism or signiﬁcant drift were
discarded and not used for further analysis. Reference-free 2D class
averaging was used to discard distorted particles. The particle population
was further improved by 3D classiﬁcation. The X-ray structure of native
CMV (PDB: 1F15)29 was low-pass-ﬁltered to 50 Å and used as an initial
template for 3D classiﬁcation and reﬁnement. A total of 3582 CMVtt830
particles from 6600 micrographs were used to solve the ﬁnal density maps
at 4.2 Å resolution, as indicated by Fourier shell correlation and 0.143 cut-
off.
Using a similar approach as previously described,30,31 the CMV was ﬁtted
in the density map as a rigid body with UCSF Chimera 32. The ﬁtting was
improved further by real-space reﬁnement using COOT 33 and Phenix 35.
Only the coordinates being reﬁned each time, with the maps kept
constant. Cross-correlation guided each round of model optimization
between the map and the model.
Production of mIL17 protein
A nucleotide fragment codon optimized for E. coli was synthesized
(GeneArt Genestring, ThermoFisher Scientiﬁc, UK) encoding the murine IL-
17 (aa 26–158, accession: NP_034682) preceded by sequences for an
initiating methionine and glycine and coding region for a hexahistidine tag
at the N-terminus of the encoded protein, was followed by additional
sequences to give a polylinker of 5 glycine and terminal cysteine at the C-
terminus. This fragment was cloned by restriction digest (NcoI/ BamHI,
NEB, UK) in to a similarly double digested prokaryotic expression vector
(pET28b, Merck, UK). Resulting clones were conﬁrmed by PCR colony
screen and sequenced using T7 promoter forward primer (TAATACGACT-
CACTATAGGG) and pET-RP reverse primer (CTAGTTATTGCTCAGCGG).
Murine IL-17 was expressed in E. coli strain BL21(DE3)Star (Thermo Fisher
Scientiﬁc, UK), culturing to OD600 of 0.7 and inducing with 1 mM IPTG
overnight (16–18 h) at 37 oC. Harvested cells were lysed in PBS, pH
7.4 supplemented with Lysonase™ as per manufacturers recommendation
(Merck, UK), incubating 1 h and sonicating lysate on ice (3 cycles of 20 s on,
20 s off, 40% power amplitude with a VibraCell ﬁtted with microtip, Sonics
and Materials Inc, US). The lysate was clariﬁed by high speed centrifugation
(15,000×g, 30 min) and the pellet was retained. The recombinant IL-17 was
puriﬁed from the insoluble fraction as previously described.18 Brieﬂy,
inclusion bodies (IBs) from the insoluble fraction were subjected to
sequential washes with 50mM Tris pH 8, 10 mM EDTA, 100mM NaCl buffer
(initially containing 0.5% Triton × 100 then 2% Triton × 100, then without
detergent). The IBs were solubilized with solubilization buffer (6 M
guanidine HCl, 10 mM Tris.HCl, 100 mM NaH2PO4, 2 mM beta-
mercaptoethanol (BME), pH 8), insoluble debris removed by centrifugation
at 10,000 g, 20 min and clariﬁed soluble fraction subjected to nickel afﬁnity
chromatography (HisTrap Excel, GE Healthcare) under denaturing condi-
tions with low pH elution (50mM NaH2PO4, 100 mM Tris, 6 M Gdn•HCl, 2
mM BME with Buffer A, adjusted to pH 6.15; and Buffer B adjusted to pH 4).
This was followed by concentration (Amicon Ultra 3000 centrifugal ﬁlters,
Merck, UK) and further puriﬁcation using size exclusion chromatography
(HiLoad Sephadex 75, GE Healthcare, UK).
Fractions containing puriﬁed mIL-17 as identiﬁed by a 16 kDa band
(predicted molecular mass of 16,378 Da) by Coomassie stained SDS-PAGE
were pooled. Note that proteins were ethanol precipitated and resus-
pended in reducing Laemmli buffer to remove guanidine prior to the
analysis by SDS-gel electrophoresis. The puriﬁed mIL-17 was still denatured
and therefore required refolding to native form. Sample was adjusted to a
concentration of < 0.2 mg/mL and refolding followed a 2-step dialysis
strategy. Dialysis tubing was subject to 3 buffer exchanges (2 L each) over
24 h with 0.5 M Arginine, 50 mM sodium phosphate (pH 8), 10% (v/v)
glycerol and redox pair (5 mM reduced glutathione, 0.5 mM oxidized
glutathione). For the second step of dialysis, samples were dialyzed for a
further 24 h in to 50mM sodium phosphate (pH 8), 10% (v/v) glycerol, with
at least 2 buffer exchanges (2 L each).
Production of psoriasis vaccine
The puriﬁed and refolded mIL-17 was conjugated to CMVTT via the
heterobifunctional crosslinker, Succinimidyl-6-[(beta-maleimidopropiona-
mido)hexanoate] (SMPH, Thermo Fisher Scientiﬁc, UK). VLPs were reacted
with 7.5-molar excess of SMPH, for 30min at room temperature (RT),
unreacted excess crosslinker being removed by 3 repeated diaﬁltration
steps using 100 k centrifugal ﬁlters. The recovered derivatised VLPs were
then mixed at equimolar concentration with mIL17 that was pre-treated
60min at RT with 10-molar excess TCEP to liberate C-terminal cystines
(dimeric IL-17 has intramolecular disulﬁde bonds forming a cysteine knot
that are typically resistant to reducing reagents without denaturation).
Coupling efﬁciency was estimated by densitometry analysis of CMVTT
bands in Coomassie stained SDS-PAGE, comparing proportions of
monomer net intensity (NI) and monomer plus IL-17 NI after correcting
for relative MW (See ﬁgure S3B). Densitometric values were provided using
Image Lab 5.0 software (Bio-rad Laboratories) or equivalent image analysis
software. Coupling or epitope density for IL17 per VLP was calculated as
follows (eq1): IL17-CMV(NI/MW) / (Σ VLP(NI/MW) + IL17-CMV(NI/MW)) x
number of protein per subunit = epitope density (ED). Expressed as a
percentage this gives an estimated coupling density of IL17-CMV of 8%,
meaning a minimum of 14 molecules of IL17 were covalently linked to
each particle (consisting of 180 CMV monomers).
In vivo clinical efﬁcacy and immunogenicity of the IL17 vaccine in
mice
In vivo clinical efﬁcacy was measured by dorsal skin and ear epidermal
thickness assessed macroscopically and with H&E histology. Ear thickness
measurements and body weight measurements were recorded at different
time intervals during the experiments using a micrometer (Mituyo catalog
nr 7301, Thickness Gage Series 7 Flat Anvil Type Dial) and a scale,
respectively. Ear samples and dorsal skin samples were taken, roughly 2 cm
by 2 cm, and ﬁxed in neutral buffered 10% formalin. 2 ml of formalin was
used per 100mg of tissue. Tissues were ﬁxed for a minimum of 48 h at RT.
Tissue was then dehydrated through a series of graded ethanol
immersions. Once ﬁxed, the tissue was processed as follows on a Leica
Peloris tissue processor: formalin × 2, 95% ethanol × 4, 99% ethanol × 4,
xylene, 99% ethanol ﬁrst parafﬁn wax and second parafﬁn wax. Wax was
melted by placing tissue cassettes in 58 oC parafﬁn bath for 15min. Mold
that left 2 mm margin of parafﬁn wax around the tissue was selected.
Molten parafﬁn was dispensed in mold and warm forceps were used to
transfer tissue into the mold, placing the cut side down. The mold was
transferred to a cold plate and gently the tissue was pressed ﬂat. With the
tissue in the desired orientation the labeled tissue cassette was added on
top of the mold as a backing. After 30min the wax was cooled and
hardened and the parafﬁn block is popped out of the mold. Tissues were
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then sectioned using a Leica microtome to 4 µM thickness. The sections
were dried in an oven at 37 oC. The tissue and parafﬁn attached to the
cassette has formed a block, which was stored at RT. Haematoxylin and
Eosin staining was performed using Leica Autostainer XL. The procedure
was as follows: tissue was placed in an oven at 60 oC for 15min.
Deparafﬁnise sections, 3 changes of xylene, 30 s each. Re-hydrate in 2
changes of absolute alcohol, 30 s each. 99% alcohol for 2 min and 95%
alcohol for 2 min. Wash in water for 30 s. Stain in Harris haematoxylin
solution for 4 min. Wash in running tap water for 1 min. Differentiate in
0.1% acid alcohol for 1 min. Wash in water for 1 min. Bluing in saturated
lithium carbonate solution for 1 min. Counterstain in eosin solution for 20 s.
Wash in tap water for 30 s. Rinse in 95% alcohol for 30 s × 2 and rinse in
99% alcohol for 30 s × 2. Rinse in Isopropyl alcohol for 30 s. Clear in 3
changes of xylene, 30 s each. Sections were coverslipped by Leica
Coverslipper CV5030 using DPX mountant.
Immunogenicity was assessed via measuring anti-IL-17A serum levels
with a series of ELISA experiments. Serum samples were acquired at
baseline, at each vaccination point and 2 weeks post ﬁnal vaccination.
Samples of up to 200 µl were acquired at each point with tail vein blood
sampling. First Nunc-Immuno 96 clear polystyrene MicroWell solid plates
were coated as follows. Recombinant murine (rm) IL-17 was diluted to a
concentration of 2 µg/ml in PBS and vortexed to allow adequate mixing.
100 µl of this mixture was added to each well of the plate using a multi-
channel pipette. The plate was covered with paraﬁlm and stored at 4 oC for
up to 72 h. Wash buffer was made using PBS with 0.05% Tween20 and
blocking buffer made from the washing buffer composed of 2% BSA in PBS
with 0.05% Tween20. The plate was removed from the fridge, the liquid
expelled and the plates washed 3 times with 200 µl wash buffer per well.
250 µl blocking buffer was added to each well and the plates left for 150
min. Serum was serial diluted in wash buffer on 96-well plates to the
concentrations 1:10, 1:100 etc. Control serum, taken before any antibody or
vaccination injections, was used in each experiment and diluted to a
concentration of 1:100. This high concentration relative to the test samples
was used to allow for enough serum to be used for all the experiments.
Liquid was discarded from the blocked plate and the plate was washed 3
times as above. 50 µl of diluted serum was transferred onto the coated
plate, with each sample a duplicate of that sample was used. Empty wells
were ﬁlled with 50 µl sterile water for standardization purposes and the
plate incubated for 90min on the shaker. Detection antibody was made
using Anti-mouse IgG labeled to alkaline phosphatase diluted in blocking
buffer to a concentration of 1:5000. Liquid was discarded from the blocked
plate and the plate was washed 3 times as above. 100 µl of detection
antibody was added to each well and the plates covered with paraﬁlm and
left to incubate on the shaker for 45min. Liquid was discarded from the
blocked plate and the plate was washed 3 times as above. 50 µl of alkaline
phosphatase yellow (pNPP) liquid substrate was added to each well and
the wells incubated on the shaker for 20min. 5 µl of stop solution (3 M
NaOH) was added to each well and the plate read in the
SpectraMaxM3 spectrophotometer at 405 nm. SoftMax Pro6.3 software
was used to read the plates. Absorbance instruments with endpoint
settings of 405 nm wavelength were used. ELISA data were analyzed using
a 3-parameter logistic ﬁt according to standard sigmoid curve equation, Y
=MAX/(1 + (x/EC50)^(SLOPE)) where the minimum was set to zero after
subtracting the H20 optical densities from test values. Curve ﬁtting was
done using the ‘solver’ add-in using the GRC-nonlinear ﬁtting algorithm.
Residual tail vein blood samples known to be highly immunogenic for
IL-17A were used to test the speciﬁcity of the immune response generated
by the vaccine on ELISA plates coated with IL-17A and IL-17F. The same
blood samples were tested for both IL-17A and IL-17F and the ELISA was
run for both at the same time to minimize variables.
Expression and puriﬁcation of Fel d 1
The sequence of Fel d 1 antigen 25,29,30 comprises of chain 1 and chain 2
that were genetically fused via a 15-aa linker sequence (GGGGS)3 and
synthesized by GeneArt (Thermo Fisher Scientiﬁc, Germany). The COOH-
terminus was modiﬁed by a histidine tag (6x His) for puriﬁcation purposes
followed by a small spacer (GGCG) including a cysteine for coupling. Our
version of the recombinant Fel d 1 has a predicted molecular mass of
20,147 Da. The encoding Fel d 1 sequence was cloned into the high level-
expression plasmid vector pET42. E. coli C2566I (NEB) were transformed
with the plasmid and cultivated at 37 °C. At a OD600 between 0.5 and 0.7
1mM IPTG was added to the culture and placed at 20 °C overnight for
soluble protein expression. Cells were harvested and separated from
supernatant by centrifugation at 4800×g for 15 min at 4 °C. The cell pellet
was resuspended in 50mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH
8.0 and sonicated for cell lysis. The solution containing the recombinant Fel
d 1 was cleared from cell debris by centrifugation at 16,000×g for 30 min at
4 °C. The supernatant was collected and puriﬁed by a Ni-NTA (Qiagen)
column using the ÄKTA puriﬁer. Recombinant Fel d1 containing a His-tag
bound to Ni-NTA and was washed with 50mM NaH2PO4, 300 mM NaCl, 50
mM imidazole, pH 8.0, ﬁnally eluted in 50mM NaH2PO4, 300mM NaCl, 250
mM imidazole, pH 8.0 and dialyzed against PBS overnight at 4 °C. The
antigen authenticity was tested in a capture ELISA (EL-FD1, Indoor
Biotechnology) using mAbs that were raised against natural Fel d 1.
Production and immunogenicity testing of Fel d 1 vaccine
The puriﬁed Fel d 1 was conjugated to CMVTT VLPs using the crosslinker
SMPH. A 10-molar excess of SMPH reacted at 23 °C for 60min shaking at
350 rpm. The side product was removed using PD10 desalting columns (GE
Healthcare). To gain access to the cysteine at the COOH-terminus of the
recombinant Fel d 1, the antigen solution reacted with a 10-molar access
of a mild reducing agent TCEP (Sigma) before a 2-molar excess of Fel d 1
was added to the derivatized CMVTT-VLP at 23 °C for 3 h at 350 rpm.
Unbound Fel d 1 protein was removed by Amicon Ultra centrifugal ﬁlter
devices (Millipore) and tested by SDS-PAGE analysis. CMV monomers
appear at ~25 kDa and Fel d 1 protein at ~20 kDa. Due to crosslinking of
subunits, derivatization by SMPH leads to the characteristic ladder of CMV
monomers, dimer, trimers, tetramers, etc. The primary coupling band
appears as one CMV monomer linked to one Fel d 1 protein at ~45 kDA.
Coupling efﬁciency was calculated by densitometry (as previously
described for IL17A-CMVTT vaccine) with a result of ~ 30% meaning 60
Fel d 1 molecules were linked to one particle.
To test immunogenicity, 8 weeks old Balb/c were immunized with 1 µg
of free Fel d 1, Fel d 1 mixed with or coupled to CMVTT VLPs in 150 µl PBS
intravenously. Blood was collected at different time points and analyzed
for anti-Fel d1 antibodies by ELISA. Natural Fel d 1 (Indoor Biotechnologies)
at 1 µg/ml was applied overnight to NUNC ELISA plates which were then
washed and blocked with 2% BSA in PBS Tween 20 (0.05%). After washing,
serially diluted mouse sera were applied to the plates. After further
washing, goat anti-mouse IgG antibody labeled with horseradish
peroxidase was applied to the plates. Following a ﬁnal washing step, O-
phenylenediamine dihydrochloride was added and, after 7 min, the
reaction stopped with 5% sulfuric acid. The conversion of OPD by HRPO
was measured at 450 nm. The titers is reported as OD50 which is the
reciprocal of the dilution which reaches half of the maximal OD value.
Basophil activation test (BAT)
The BAT assay (Bühlmann Co.) using whole blood from allergic patients
was tested for the up-regulation of the degranulation marker CD63 on
basophils (CCR3+)31 upon incubation with Fel d 1 and Fel d 1 couples to
CMVTT-VLPs by ﬂow cytometry using a BD Fortessa. Brieﬂy, 100 μl of
stimulation buffer was mixed with 50 μl of EDTA-treated whole blood. In
addition, 50 μl of dilutions of natural Fel d1, recombinant Fel d1 and
recombinant Fel d 1 conjugate (Fel-CMVTT) were added. Positive control
solutions including an mAb against FcεRI as well as an unspeciﬁc cell
activator (fMLP) were also tested in the assay. Staining dye (20 μl per
sample), containing anti-CCR3 Ab labeled to PE and anti-CD63 Ab labeled
to FITC, was added and incubated at 37 °C for 25min. Erythrocytes were
subsequently lysed adding lysis buffer. After 10 min incubation, the
samples were centrifuged at 500×g for 5 min and washed with wash buffer
(PBS containing 2% FCS). After a second centrifugation step, the cell pellets
were resuspended in wash buffer and acquired using a ﬂow cytometer
(FACS BD Fortessa). The samples were analyzed by DIVA software. The
percentage of the CD63 expression on CCR3+ basophils was analyzed.
Fel d 1 allergen challenge in-vivo
For Fel d 1 sensitization, two groups of 5 female 6-wk-old BALB/c mice
were injected with 1 μg natural Fel d 1 (Indoor biotechnologies) mixed in
200 µl Alum (10 mg/ml Al(OH)3; Alhydrogel adjuvant 2%, InvivoGen) at day
0, 7 and 14 intraperitoneal. At day 28 mice were vaccinated with 30 μg
vaccine Fel-CMVTT or only CMVTT-VLPs subcutaneously.
For the induction of anaphylaxis, two weeks after vaccination on study
day 42 mice were challenged with 3 μg natural Fel d1 in 150 μl PBS
intravenously. The rectal core temperature was measured with a rectal
probe digital thermometer (MiniTemp, Vetronic Services LTD) every 10min
for 50min after intravenous antigen challenge.
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Production of Alzheimer’s vaccine
CMVTT VLPs or CMV wildtype (WT) VLPs reacted with a 7.5-molar excess of
the crosslinker SMPH for 1 h at RT. A short 6-aa sequence (DAEFRH) from
the N-terminus from the full length Aβ peptide (1–42 aa) encoding with
terminal cysteine residue (GGC) purchased from Dr. Petra Henklein, Charite,
Berlin, Germany was conjugated in a 5-molar excess to the derivatised
CMVTT or CMVWT particles for 3 h at RT. The vaccine was analyzed by SDS-
PAGE to conﬁrm coupling of peptide to CMVTT or CMVWT particles. CMV
monomers appear at ~25 kDa. Due to crosslinking of subunits, derivatiza-
tion by SMPH leads to the characteristic ladder of CMV monomers, dimer,
trimers, tetramers, etc. Coupling bands appear above CMV monomer when
one peptide (~1 kDa) bound to CMV momoner (coupling product ~26 kDa)
or two peptides bound to CMV monomer (coupling product ~27 kDa).
Coupling bands of peptide(s) to CMV dimers appear above CMV dimer
accordingly. The coupling efﬁciency (described previously for IL17A-CMVTT
vaccine) was calculated by densitometry resulting in ~60% meaning
approximately 108 peptide molecules were linked to each VLP.
Immunogenicity assessment of Alzheimer’s vaccine and
assessment of TT enhancement
To test the TT enhancement, 6 months old female Balb/C mice were
primed with Infanrix (1/5 dose per mouse). A control group of mice were
left un-primed. After three weeks, mice were immunized with 1 µg Aβ1–6-
CMVTT- or Aβ1–6-CMVWT- vaccine intravenously. Blood was collected on
days 0, 3, 7 and 14 and analyzed for serum Aβ speciﬁc IgG antibodies as
described previously. The antibody titers is reported as OD50 which is the
reciprocal of the dilution which reaches half of the maximal OD value.
Immunohistology of Alzheimer’s patients’ brain sections
Sections of parafﬁn embedded brain (hippocampus) tissue of an
Alzheimer’s patient were prepared with a microtome. After deparafﬁnising,
sections were blocked in BSA with normal horse serum. A monoclonal
antibody raised against Aβ1–17 (Abcam ab11132), or by Protein G-puriﬁed
mouse serum from day 0 (pre-immune) or day 56 (post-immune) after one
immunization were applied to sections for 1 h at RT. To detect speciﬁc
binding all pre-treated brain sections were incubated with a biotinylated
horse anti-mouse IgG (Vectorlabs BA2000) for 30min at RT, ﬁrst and next,
incubated with streptavidin labeled with AP. Binding was visualized by
substrate Fast Red from Sigma. Subsequently, in order to visualize nuclei a
counterstain using hematoxylin was performed. Stained slides were
digitalized at 0.25 μm per pixel resolution using a ScanScope XT (Aperio,
Vista, CA, USA). Full-slide scans were stored as high-resolution (0.21
microns/pixel). Regions of interest were processed using ImageScope
software (Aperio).
Data availabality statement
The cryo-electron microscopy density map for CMV-tt VLP structures have
deposited with the Electron Microscopy Data Bank: EMD-3855 and
associated atomic coordinates submitted to the Protein Data Bank with
accession number PDB: 5OW6.
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